№ 5 / 2017 / 21-25

MANAGEMENT OF RISKS OF VASCULAR AND THROMBOTIC COMPLICATIONS DEVELOPMENT UNDER THE USE OF HORMONAL CONTRACEPTION

Author: Marinkin I.O.¹, Sokolova T.M.², Mishenina S.V.³, Emedova T.A.⁴, Madonov P.G.⁵, Mazarchuk N.E.⁶, Baykalov G.I.⁷

Abstract

The article presents a methodology for managing the risks of thrombotic and vascular complications in women using hormonal contraception. The test lists of the risk assessment for thrombosis and vascular insufficiency have been developed. The presented method became the basis for creating the regional register of women with complications of hormonal contraception and hormonal replacement therapy.

Key words

thrombotic complications, vascular complications, hormonal contraception

References

Grebennikova G.A. Management of side effects of combined hormonal contraception (review of international recommendations) // Reproduktivnaya meditsina = Reproductive medicine. 2014. (3–4). 107-109. [In Russian].
Hugon-Rodin J., Gompel A., Plu-Bureau G. Epidemiology of hormonal contraceptives-related venous thromboembolism // Eur. J. Endocrinol. 2014. 171. (6). R221–R230.
Khvoshchina T.N. Prevention of hemocoagulation disorders in women taking contraceptives with an antiandrogenic effect: abstract of thesis…doctor of medical sciences. Tyumen', 2014. [In Russian].
Kiryushchenkov P.A., Tambovtseva M.A. Rational contraception: minimizing the risks // Ginekologiya = Gynecology. 2015. 17. (2). 41–44. [In Russian].
Lidegaard О. Hormonal contraception, thrombosis and age // Expert Opin. Drug Saf. 2014. 13. (10). 1353-1360.
Momot A.P., Taranenko I.A., Tsyvkina L.P. Evolution of ideas on thrombophilia and its role in human reproduction problems // Akusherstvo i ginekologiya = Obstetrics and Gynecology. 2013. (2). 4-9. [In Russian].
Moyer V.A. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force Recommendation Statement // Ann. Intern. Med. 2013. 158. (1). 47-54.
Passman M.A., McLafferty R.B., Lentz M.F. et al. Validation of Venous Clinical Severity Score (VCSS) with other venous severity assessment tools from the American Venous Forum, National Venous Screening Program // J. Vasc. Surg. 2011.54. (6, Suppl.). 2S-9S.
Shishkova V.N. Modern oral contraception and risk of thrombosis // Zdorov'ye zhenshchiny = Health of woman. 2013. (10). 71. [In Russian].
Shishkova V. Safety of hormonal contraceptives: thrombotic risk and metabolic disturbances // Vrach = Physician. 2013. (7). 13-18. [In Russian].
Tepper N.K., Marchbanks P.A., Curtis K.M. Superficial venous disease and combined hormonal contraceptives: a systematic review // Contraception. 2016. 94. (3). 275-279.
Tsukanov Yu.T., Tsukanov A.Yu. Experience with six-month administration of red vine leaf extract in hormone-induced phlebopathy // Angiologiya i sosudistaya khirurgiya = Angiology and Vascular Surgery. 2014. 20. (3). 102-107. [In Russian].
Tsukanov Yu.T., Tsukanov A.Yu., Bazhenov A.Yu. et al. Medication correction of negative phlebotrophic effects of hormone replacement therapy in women // Angiologiya i sosudistaya khirurgiya = Angiology and Vascular Surgery. 2009. 15. (3). 87-91. [In Russian].
Wells P.S., Anderson D.R., Bormanis J. et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management // Lancet. 1997. 350. (9094). 1795-1798.

About Authors (Correspondence):

Madonov P.G. – doctor of medical sciences, professor, head of department of for pharmacology, clinical pharmacology and evidentiary medicine, e-mail: madonov@scpb.ru

Full Text

snmzh_5-2017_marinkin_i_dr.pdf

Received: 30/10/2017

Accepted: 30/10/2017